Literature DB >> 2841334

Expression of functional human C1 inhibitor in COS cells.

E Eldering1, J H Nuijens, C E Hack.   

Abstract

Full length human C1 inhibitor cDNA was cloned into a vector suitable for transient expression in COS-1 cells. Transfected COS cells secreted an immunoreactive protein of Mr approximately 110,000 that appeared to be functionally equivalent to the plasma-derived protein as established by the following criteria: 1) ability to form sodium dodecyl sulfate-stable complexes with C1s, factor XIIa, and kallikrein; 2) inhibition of C1s-mediated C4 consumption; and 3) susceptibility to inactivation by the nontarget proteinase elastase. Quantitation of secreted recombinant C1 inhibitor by radioimmunoassay indicated that 72 h after transfection the level was approximately 2.2 micrograms/ml. Treatment of transfected cells with tunicamycin resulted in secretion of a protein of Mr approximately 90,000 that was also capable of complex formation with C1s.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841334

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Therapeutic approaches in hereditary angioedema.

Authors:  Sabina Antonela Antoniu
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

2.  Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

Authors:  Angelo Agostoni; Emel Aygören-Pürsün; Karen E Binkley; Alvaro Blanch; Konrad Bork; Laurence Bouillet; Christoph Bucher; Anthony J Castaldo; Marco Cicardi; Alvin E Davis; Caterina De Carolis; Christian Drouet; Christiane Duponchel; Henriette Farkas; Kálmán Fáy; Béla Fekete; Bettina Fischer; Luigi Fontana; George Füst; Roberto Giacomelli; Albrecht Gröner; C Erik Hack; George Harmat; John Jakenfelds; Mathias Juers; Lajos Kalmár; Pál N Kaposi; István Karádi; Arianna Kitzinger; Tímea Kollár; Wolfhart Kreuz; Peter Lakatos; Hilary J Longhurst; Margarita Lopez-Trascasa; Inmaculada Martinez-Saguer; Nicole Monnier; István Nagy; Eva Németh; Erik Waage Nielsen; Jan H Nuijens; Caroline O'grady; Emanuela Pappalardo; Vincenzo Penna; Carlo Perricone; Roberto Perricone; Ursula Rauch; Olga Roche; Eva Rusicke; Peter J Späth; George Szendei; Edit Takács; Attila Tordai; Lennart Truedsson; Lilian Varga; Beáta Visy; Kayla Williams; Andrea Zanichelli; Lorenza Zingale
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

3.  Production of multidomain complement glycoproteins in insect cells.

Authors:  P Závodzky; S Cseh
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

4.  Plasma levels of C1- inhibitor complexes and cleaved C1- inhibitor in patients with hereditary angioneurotic edema.

Authors:  M Cugno; J Nuijens; E Hack; A Eerenberg; D Frangi; A Agostoni; M Cicardi
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

5.  Proteolytic inactivation of plasma C1- inhibitor in sepsis.

Authors:  J H Nuijens; A J Eerenberg-Belmer; C C Huijbregts; W O Schreuder; R J Felt-Bersma; J J Abbink; L G Thijs; C E Hack
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

6.  Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.

Authors:  E Eldering; C C Huijbregts; J H Nuijens; A J Verhoeven; C E Hack
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

7.  Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.

Authors:  E Verpy; E Couture-Tosi; E Eldering; M Lopez-Trascasa; P Späth; T Meo; M Tosi
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

8.  Unique C1 inhibitor dysfunction in a kindred without angioedema. II. Identification of an Ala443-->Val substitution and functional analysis of the recombinant mutant protein.

Authors:  R Zahedi; J J Bissler; A E Davis; C Andreadis; J J Wisnieski
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

9.  Conestat alfa for the treatment of angioedema attacks.

Authors:  Benjamin Davis; Jonathan A Bernstein
Journal:  Ther Clin Risk Manag       Date:  2011-07-01       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.